Published 2nd October 2020

MINIject’s STAR-I and II trial data to be presented at ESCRS

Positive results from two clinical trials of iSTAR Medical’s micro-invasive glaucoma surgery (MIGS) implant MINIjectTM  will be presented at the European Society of Cataract and Refractive Surgery (ESCRS) meeting on October 2-4.


The final two-year data from the STAR-I trial and the six-month follow-up data from the STAR-II European trial showed consistently outstanding reduction of intraocular pressure (IOP) and reduced the need for IOP-lowering medication in over 50 patients with open angle glaucoma, following standalone MINIject implantation.


The data available so far suggest that MINIject works effectively, may help prevent risks, and improves overall patient management compared with other surgical treatments. Professor Julián García-Feijoó from Hospital Clinico San Carlos, Complutense University, Madrid (Spain), who will present the STAR-II trial results at the ESCRS meeting.

iSTAR Medical’s team will welcome viewers at its virtual booth in Hall 3.

Share this entry
scroll to up
Sign up to receive company news alerts